Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review
| Autor: | Ahmed M. Al-Abd, Abdulmohsin J. Alamoudi, Ashraf B. Abdel-Naim, Thikryat A. Neamatallah, Osama M. Ashour |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: | |
| Zdroj: | Journal of Advanced Research, Vol 8, Iss 6, Pp 591-605 (2017) |
| Druh dokumentu: | article |
| ISSN: | 2090-1232 2090-1224 |
| DOI: | 10.1016/j.jare.2017.06.006 |
| Popis: | Recent strategies for the treatment of cancer, other than just tumor cell killing have been under intensive development, such as anti-angiogenic therapeutic approach. Angiogenesis inhibition is an important strategy for the treatment of solid tumors, which basically depends on cutting off the blood supply to tumor micro-regions, resulting in pan-hypoxia and pan-necrosis within solid tumor tissues. The differential activation of angiogenesis between normal and tumor tissues makes this process an attractive strategic target for anti-tumor drug discovery. The principles of anti-angiogenic treatment for solid tumors were originally proposed in 1972, and ever since, it has become a putative target for therapies directed against solid tumors. In the early twenty first century, the FDA approved anti-angiogenic drugs, such as bevacizumab and sorafenib for the treatment of several solid tumors. Over the past two decades, researches have continued to improve the performance of anti-angiogenic drugs, describe their drug interaction potential, and uncover possible reasons for potential treatment resistance. Herein, we present an update to the pre-clinical and clinical situations of anti-angiogenic agents and discuss the most recent trends in this field. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|